Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens

Author:                    

Publisher: Spandidos Publications

ISSN: 1792-1074

Source: Oncology Letters, Vol.2, Iss.2, 2011-01, pp. : 247-251

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content